过继细胞疗法（ACT）是一种快速发展的抗癌策略，在治疗各种癌症类型方面已显示出前景。 ACT的概念涉及在体外激活患者自身的免疫细胞，然后将其转移回患者体内以识别并消除癌细胞。目前常用的ACT包括肿瘤浸润淋巴细胞（TIL）、基因工程免疫细胞和树突状细胞（DC）疫苗。随着细胞培养和基因工程技术的进步，ACT已应用于临床治疗恶性血液病，许多基于ACT的新疗法正处于不同阶段的临床试验。这里介绍了代表性的 ACT 方法，并讨论了 ACT 临床转化的机遇和挑战。© 2023 作者。河南大学和约翰·威利出版的《探索》

Adoptive cell therapy (ACT) is a rapidly growing anti-cancer strategy that has shown promise in treating various cancer types. The concept of ACT involves activating patients' own immune cells ex vivo and then transferring them back to the patients to recognize and eliminate cancer cells. Currently, the commonly used ACT includes tumor-infiltrating lymphocytes (TILs), genetically engineered immune cells, and dendritic cells (DCs) vaccines. With the advancement of cell culture and genetic engineering techniques, ACT has been used in clinics to treat malignant hematological diseases and many new ACT-based regimens are in different stages of clinical trials. Here, representative ACT approaches are introduced and the opportunities and challenges for clinical translation of ACT are discussed.© 2023 The Authors. Exploration published by Henan University and John Wiley & Sons Australia, Ltd.